|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.072 AUD | +2.86% |
|
-20.00% | +227.27% |
| 30/04 | Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury | MT |
| 18/04 | Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024 |
Nyrada Inc. reported earnings results for the full year ended June 30, 2023. For the full year, the company reported revenue was AUD 1.58 million compared to AUD 1.11 million a year ago. Net loss was AUD 7.78 million compared to AUD 3.96 million a year ago.
Basic loss per share from continuing operations was AUD 0.05 compared to AUD 0.03 a year ago. Diluted loss per share from continuing operations was AUD 0.05 compared to AUD 0.03 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +227.27% | 8.53M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
NYRADA INC. 